Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 15/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.69 |
| ▸ | HRH1 | P35367 | 4/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3184023 | 1.00 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3186814 | 1.00 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3192547 | 1.00 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3195616 | 0.92 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3187901 | 0.92 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3192578 | 0.92 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3187887 | 0.92 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3187896 | 0.92 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3192592 | 0.92 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3192790 | 0.92 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1950348-A | Substituted morpholino compounds for the treatment of central nervous system disorders | WARNER LAMBERT CO (US) | 2007-04-18 | — | — | CN | claimed |
| EP-1745029-A1 | SUBSTITUTED MORPHOLINE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Warner-Lambert Company LLC (US) | 2007-01-24 | — | — | EP | claimed |
| WO-2005105763-A1 | SUBSTITUTED MORPHOLINE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-10 | — | — | WO | claimed |
| US-20050245519-A1 | Substituted morpholine compounds for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2005-11-03 | — | — | US | claimed |
| EP-1556393-B1 | NOVEL CYCLIC PHOSPHATE DIESTERS OF 1,3-PROPANE-1-ARYL DIOLS AND THEIR USE IN PREPARING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-7666855-B2 | 2′-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7659394-B2 | Substituted morpholine compounds for the treatment of central nervous system disorders | PFIZER INC (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659394-B2 | Substituted morpholine compounds for the treatment of central nervous system disorders | PFIZER INC (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659394-B2 | Substituted morpholine compounds for the treatment of central nervous system disorders | PFIZER INC (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090131370-A1 | Novel Nucleoside Derivatives | METABASIS THERAPEUTICS , INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| US-7498320-B2 | Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070021388-A1 | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2007-01-25 | — | — | US | disclosed |
| EP-1745029-A1 | SUBSTITUTED MORPHOLINE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Warner-Lambert Company LLC (US) | 2007-01-24 | — | — | EP | disclosed |
| US-7148349-B2 | Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| WO-2005105763-A1 | SUBSTITUTED MORPHOLINE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245519-A1 | Substituted morpholine compounds for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2005-11-03 | — | — | US | disclosed |
| US-20050182252-A1 | Hepatitis C viral infection; 2'-C-beta-methyl-7-deazaadenosine; trans-4-(aryl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinanes | METABASIS THERAPEUTICS, INC. | 2005-08-18 | — | — | US | disclosed |
| US-20040192651-A1 | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131370-A1 | Novel Nucleoside Derivatives | SLC29A1, SLC29A2, PNP | SLC6A2 1036/4885SLC6A4 994/4885SLC6A3 955/4885 |
| US-20050182252-A1 | Hepatitis C viral infection; 2'-C-beta-methyl-7-deazaadenosine; trans-4-(aryl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinanes | MTAP, NT5C3B, ADAR | SLC6A2 1577/4885SLC6A4 2344/4885SLC6A3 1425/4885 |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | SLC6A2 1249/4885SLC6A4 2515/4885SLC6A3 1557/4885 |
| US-20050245519-A1 | Substituted morpholine compounds for the treatment of central nervous system disorders | CNR1, OPRM1, HCRTR1 | SLC6A2 124/4885SLC6A4 235/4885SLC6A3 93/4885 |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MTAP, NT5C3B, NSUN2 | SLC6A2 1416/4885SLC6A4 1531/4885SLC6A3 1452/4885 |
| US-20040192651-A1 | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | PNP, CYP2S1, CYP2F1 | SLC6A2 1690/4885SLC6A4 2495/4885SLC6A3 941/4885 |
| US-20070021388-A1 | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | PNP, CYP2S1, TYMP | SLC6A2 1721/4885SLC6A4 2501/4885SLC6A3 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.